OakChart

Indaptus Therapeutics Inc

INDPHealthcare·Biotechnology·USA·Small·NASD·Nov 11 • 3:16 PM ET

3.18+0.28 (9.65%)
2026-11-11 21:16 CET
Market cap
445.38 USD m
Revenue, TTM
0.00 USD m
Net income, TTM
-15.42 USD m
Free cash flow, TTM
-15.79 USD m
EPS diluted, TTM
-6.97
P/E
-
Compare

Price

INDP against its 20, 50 and 200-day averages
2050200earnings
2.004.006.0022.1M44.3MVolumeMay 26Jun 26Jul 26Aug 26Sep 26Oct 26Nov 26INDPclose 3.1820-day 3.1350-day 2.88200-day 2.313.1852w high52w low

46.6% under the 52-week high of 5.96 on 4 Jun 2026. 52-week low 0.92 on 22 May 2026. Last 15 sessions, 34.2% high to low

Volume 0.26× normal · the line is the 50-bar volume average

Profile

INDP
52-week range, 45% of the way up
0.925.96

Indaptus Therapeutics, Inc. is a clinical biotechnology company. The firm engages in the development of a novel and patented systemically-administered anti-cancer and anti-viral immunotherapy. It created patented treatment methods and associated patented compositions for attenuation and killing of non-pathogenic, Gram-negative bacteria. The company was founded by Michael James Newman on February 24, 2021 and is headquartered in New York, NY.

Employees5
IPODec 26, 2012
Beta0.94
ATR, 14d0.37
Rel volume0.26
Short float15.78%
Insider own95.30%
Inst own0.35%

Snapshot

6 groups

Valuation

Index-
Market Cap488.38M
Enterprise Value476.83M
Income-15.42M
Sales0.00M
Book/sh0.09
Cash/sh0.08
Dividend Est.-
Dividend TTM-
Dividend Ex-Date-
Dividend Gr. 3/5Y- -
Payout-
Employees5
IPODec 26, 2012

Ratios

P/E-
Forward P/E-
PEG-
P/S-
P/B37.26
P/C42.28
P/FCF-
EV/EBITDA-
EV/Sales-
Quick Ratio19.48
Current Ratio19.48
Debt/Eq0.00
LT Debt/Eq0.00
Option/ShortNo / Yes

Earnings

EPS (ttm)-6.97
EPS next Y-
EPS next Q-
EPS this Y-
EPS next Y-
EPS next 5Y-
EPS past 3/5Y23.68% 36.34%
Sales past 3/5Y- -
EPS Y/Y TTM81.43%
Sales Y/Y TTM-
EPS Q/Q99.83%
Sales Q/Q-
EarningsAug 13 BMO
EPS/Sales Surpr.- -

Ownership

Insider Own95.30%
Insider Trans0.00%
Inst Own0.35%
Inst Trans166.49%
ROA-163.84%
ROE-318.04%
ROIC-135.62%
Gross Margin-
Oper. Margin-
Profit Margin-
SMA201.57%
SMA5010.56%
SMA20037.90%
Trades-

Technical

Shs Outstand133.24M
Shs Float7.22M
Short Float15.78%
Short Ratio1.26
Short Interest1.14M
52W High5.96 -46.65%
52W Low0.92 245.64%
Volatility13.53% 12.37%
ATR (14)0.37
RSI (14)53.01
Beta0.94
Rel Volume0.26
Avg Volume907.04K
Volume214,391

Performance

Perf Week-3.64%
Perf Month33.05%
Perf Quarter199.99%
Perf Half Y81.71%
Perf YTD9.27%
Perf Year16.91%
Perf 3Y-95.13%
Perf 5Y-98.45%
Perf 10Y-99.97%
Recom1.00
Target Price10.00
Prev Close2.90
Price3.18
Change %9.65%

Peers

Mkt cap
TickerCompanyMkt cap
CYPHCypherpunk Technologies Inc217.15M
XCURExicure Inc7.17M
CNTNCanton Strategic Holdings Inc151.00M
LITSLite Strategy Inc29.46M
KTTAPasithea Therapeutics Corp17.94M
TCRTAlaunos Therapeutics Inc6.77M
CDTCDT Equity Inc0.52M
ELABPMGC Holdings Inc1.26M
ONCOOnconetix Inc2.22M
SCNIScinai Immunotherapeutics Ltd ADR0.73M

Held by

AUM
TickerCompanyAUM
VXFVanguard Extended Market Index ETFAUM: 30.47B
MSSMMorgan Stanley Pathway Small-Mid Cap Equity ETFAUM: 705.72M

News

latest 14 of 200
  • MRNA On Track To Be September's No. 2 S&P 500 Stock But These 5 Smaller Health Care Names Did Even Better (Stocktwits) +6.10%
  • Indaptus Therapeutics Reports Second Quarter 2026 Financial Results and Provides Corporate Update (GlobeNewswire)
  • Indaptus Therapeutics Reports First Quarter 2026 Financial Results and Provides Corporate Update (GlobeNewswire) -9.14%
  • Indaptus Enters Into $6 Million Securities Purchase Agreement with Investor David E. Lazar (GlobeNewswire) +6.67%
  • Indaptus Therapeutics Chief Scientific Officer Dr. Michael Newman to Present at the Donor Selection & Cell Source Summit (GlobeNewswire) -9.56%
  • Indaptus Therapeutics Reports Third Quarter 2025 Financial Results and Provides Corporate Update (GlobeNewswire) +6.25%
  • Indaptus Therapeutics Provides Clinical Update (GlobeNewswire) -14.63% -28.35%
  • Indaptus Therapeutics to Present at the H.C. Wainwright 27?? Annual Global Investment Conference (GlobeNewswire) -5.34% -12.24%
  • Indaptus Therapeutics Reports Second Quarter 2025 Financial Results and Provides Corporate Update (GlobeNewswire)
  • Indaptus Therapeutics, Inc. Announces Additional Sale of $3.4 Million in Private Placement of Convertible Notes and Warrants (GlobeNewswire) +5.89%
  • Indaptus Therapeutics Announces Reverse Stock Split (GlobeNewswire) -18.29%
  • Wall Street Eyes Breakout Cancer Therapies Amid Soaring Drug Prices (PR Newswire) -9.92%
  • Indaptus Therapeutics, Inc. Announces Sale of $2.3 Million in Private Placement of Convertible Notes and Warrants (GlobeNewswire)
  • Indaptus Therapeutics Doses First Patient in Phase 1b/2 Combination Study of Decoy20 with PD-1 Checkpoint Inhibitor Tislelizumab (GlobeNewswire)

Quarterly earnings

actual against estimate
PeriodReportedEPS actEPS estEPS repSales actSales estAnalysts
2026Q22026-08-13-0.020--2.9800.00--
2026Q12026-05-15-0.230--0.2320.00--
2025Q32025-11-12-2.980-4.170-2.9840.00-1
2025Q22025-08-13-9.090-9.240-9.0950.00-1
2025Q12025-05-14-8.960-5.040-8.9990.00-1
2024Q42025-03-13-10.360-13.160-10.4330.00-1
2024Q32024-11-12-8.960-13.440-9.0360.00-2
2024Q22024-08-12-13.160-15.400-13.1590.00-2
2024Q12024-05-08-12.600-15.960-12.6250.00-1
2023Q42024-03-13-12.880-15.120-13.341--2
2023Q32023-11-06-13.160-14.560-13.073--2
2023Q22023-08-14-10.920-16.240-10.816--2
2023Q12023-05-11-14.280-13.860-14.176--2
2022Q42023-03-17-13.160-12.600-12.374--2
2022Q32022-11-10-11.760-14.280-11.752--1
2022Q22022-08-08-12.880-13.440-13.0040.000.001

Annual earnings

PeriodEPS actEPS estEPS repSales actSales est
2018FY-3,136-2,952-3,1270.000.00
2019FY-3,158-3,002-3,1570.000.75
2020FY-456.96-478.61-206.420.000.00
2021FY-52.920-130.34-52.784--
2022FY-48.440-48.720-48.539--
2023FY-51.240-54.460-51.4050.00-
2024FY-45.080-47.880-45.0800.00-
2025FY--20.790-21.580--
2026FY--6.340---
2027FY--4.420---
2028FY-0.790--42.39
2029FY-6.400--123.05

Estimate revisions

last 14 periods
PeriodTypeDateEstimatesUpDownMeanLowHigh
2026Q3R2026-01-26100-1.46-1.46-1.46
2026Q3R2025-11-12110-1.46-1.46-1.46
2026Q3R2025-11-11100-3.22-3.22-3.22
2026Q3R2025-11-10100-3.22-3.22-3.22
2026Q3R2025-11-09100-3.22-3.22-3.22
2026Q3R2025-11-08100-3.22-3.22-3.22
2026Q3R2025-11-07100-3.22-3.22-3.22
2026Q3R2025-11-06100-3.22-3.22-3.22
2026Q3R2025-11-05100-3.22-3.22-3.22
2026Q3R2025-11-04100-3.22-3.22-3.22
2026Q3R2025-11-03100-3.22-3.22-3.22
2026Q3R2025-11-02100-3.22-3.22-3.22
2026Q3R2025-11-01100-3.22-3.22-3.22
2026Q3R2025-10-31100-3.22-3.22-3.22

Estimate history

EPS, annual-3666.835-3126.86-3156.742-206.423-52.784-48.539-51.405-44.958-21.58-6.9744
Period201720182019202020212022202320242025TTM
EPS, quarterly-13.159-9.036-10.433-8.999-9.095-2.984-3.743-0.232-0.016
PeriodQ2 '24Q3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26
Sales, annual0000000000
Period201720182019202020212022202320242025TTM
Sales, quarterly000000000
PeriodQ2 '24Q3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26
Shares, annual0.0120.0150.0160.0170.2950.30.30.4292.167133.242
Period201720182019202020212022202320242025MRQ
Shares, quarterly0.3050.3640.4290.5730.6051.6422.167113.242133.242
PeriodQ2 '24Q3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26

Income statement, annual

Currency USD, millions
MetricTTM2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY
Total Revenue0.000.000.000.000.000.000.000.000.00
Cost of Goods Sold Incl. D&A0.000.000.000.000.000.000.000.850.86
Gross Profit0.000.00-0.00-0.00-0.00-0.00-0.00-0.85-0.86
Selling, General and Administrative Excl. Other14.7719.8315.3716.3814.917.733.6034.0942.47
Research and Development5.229.347.257.626.322.522.6626.6635.40
Other Operating Expense0.000.000.000.000.000.000.000.000.00
Operating Income-14.77-19.83-15.37-16.38-14.91-7.73-3.60-34.95-43.33
Interest Expense--0.00-0.000.000.000.020.02
Unusual Expense0.781.150.000.000.000.000.0013.650.19
Net Income Before Taxes-15.42-20.85-15.02-15.42-14.32-7.71-3.58-46.96-43.44
Income Taxes0.000.000.000.000.000.000.000.640.10
Consolidated Net Income-15.42-20.85-15.02-15.42-14.32-7.71-3.58-47.60-43.54
Net Income From Continuing Operations-15.42-20.85-15.02-15.42-14.32-7.71-3.58-47.60-43.54
Net Income-15.42-20.85-15.02-15.42-14.32-7.71-3.58-47.60-43.54
EPS (Recurring)-0.13-20.74-44.96-51.41-48.54-52.78-206.42-2,523.05-3,117.11
EPS (Basic, Before Extraordinaries)-6.97-21.58-44.96-51.41-48.54-52.78-206.42-3,156.74-3,126.86
EPS (Diluted)-6.97-21.58-44.96-51.41-48.54-52.78-206.42-3,156.74-3,126.86
EBITDA-14.77-19.83-15.37-16.38-14.91-7.73-3.60-34.09-42.47
Non-Operating Income (Expense)0.130.140.340.950.590.020.021.650.11
Other After Tax Adjustments0.000.000.000.000.000.000.000.000.00
Stock Option Compensation Expense1.231.362.312.972.961.510.142.482.45
Shares Outstanding133.242.170.430.300.300.290.020.020.01
Market Capitalization445.38445.3810.1214.7911.9747.0714.9117.95250.58

Income statement, quarterly

Currency USD, millions
Metric2026Q22026Q12025Q42025Q32025Q22025Q12024Q42024Q3
Total Revenue0.000.000.000.000.000.000.000.00
Cost of Goods Sold Incl. D&A0.000.000.000.000.000.000.000.00
Gross Profit0.000.000.000.000.000.000.000.00
Selling, General and Administrative Excl. Other1.812.168.162.654.464.574.173.14
Research and Development0.360.492.851.522.172.812.481.47
Other Operating Expense0.000.000.000.000.000.000.000.00
Operating Income-1.81-2.16-8.16-2.65-4.46-4.57-4.17-3.14
Interest Expense-0.00-0.00-0.000.000.00
Unusual Expense0.000.410.000.370.790.000.000.00
Net Income Before Taxes-1.79-2.54-8.11-2.98-5.23-4.53-4.13-3.07
Income Taxes0.000.000.000.000.000.000.000.00
Consolidated Net Income-1.79-2.54-8.11-2.98-5.23-4.53-4.13-3.07
Net Income From Continuing Operations-1.79-2.54-8.11-2.98-5.23-4.53-4.13-3.07
Net Income-1.79-2.54-8.11-2.98-5.23-4.53-4.13-3.07
EPS (Recurring)-0.02-0.21-3.74-2.73-8.14-9.00-10.43-9.04
EPS (Basic, Before Extraordinaries)-0.02-0.23-3.74-2.98-9.10-9.00-10.43-9.04
EPS (Diluted)-0.02-0.23-3.74-2.98-9.10-9.00-10.43-9.04
EBITDA-1.81-2.16-8.16-2.65-4.46-4.57-4.17-3.14
Non-Operating Income (Expense)0.010.030.040.040.020.040.040.07
Other After Tax Adjustments0.000.000.000.000.000.000.000.00
Stock Option Compensation Expense0.060.230.790.150.180.240.300.44
Shares Outstanding133.24113.242.171.640.600.570.430.36
Market Capitalization445.384.085.103.18168.848.8210.1212.64

Balance sheet, annual

Currency USD, millions
Metric2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY
Cash & Short Term Investments8.515.7913.3626.4339.131.6410.0640.5855.22
Short Term Receivables0.000.000.000.000.020.003.492.030.48
Inventories0.000.000.000.000.000.000.000.000.00
Other Current Assets0.800.830.630.811.230.090.200.950.65
Total Current Assets9.316.6214.0027.2440.391.7313.7443.5656.34
Net Property, Plant & Equipment0.000.080.170.080.170.003.8212.238.21
Total Investments and Advances0.000.000.000.000.000.000.000.000.00
Intangible Assets0.00-------0.00
Deferred Tax Assets0.00-----0.000.280.00
Other Assets0.000.640.750.740.020.043.725.430.00
Total Assets9.317.3414.9228.0640.581.7821.2861.5164.55
Short Term Debt Incl. Current Port. of LT Debt0.000.080.100.080.100.000.540.000.00
Accounts Payable0.540.870.811.382.640.163.512.851.85
Other Current Liabilities5.612.441.871.971.871.864.294.813.89
Total Current Liabilities6.163.392.773.434.602.028.347.665.75
Long Term Debt0.000.000.070.000.070.000.800.000.00
Provision for Risks Charges0.000.000.000.000.000.000.000.000.00
Deferred Tax Liabilities0.00--------
Other Liabilities0.000.000.000.000.000.000.600.310.00
Total Liabilities6.163.392.853.434.682.029.747.965.75
Non-Equity Reserves0.000.000.000.000.000.000.000.000.00
Preferred Stock - Carrying Value0.010.000.000.000.000.010.000.000.00
Common Equity3.143.9412.0824.6335.90-0.2511.5453.5558.80
Total Shareholders Equity3.153.9412.0824.6335.90-0.2411.5453.5558.80
Accumulated Minority Interest0.000.000.000.000.000.000.000.000.00
Total Equity3.153.9412.0824.6335.90-0.2411.5453.5558.80
Total Liabilities & Stockholders Equity9.317.3414.9228.0640.581.7821.2861.5164.55
Book Value Per Share1.459.1940.2582.09121.71-14.17719.893,609.095,051.30
Tangible Book Value Per Share1.459.1940.2582.09121.71-14.17719.893,609.095,051.30
Full-Time Employees5776545498370
Price to Book Ratio33.982.560.960.431.311.031.564.681.95
Return on Assets-250.45-134.95-71.76-41.73-25.09-31.09-114.99-69.08-64.77
Return on Equity-587.59-187.52-84.04-47.32-30.58-63.45-146.28-77.52-70.94
Return on Invested Capital-661.54-380.80-126.94-58.15-21.44--385.92-81.32-49.16
Quick Ratio1.511.955.057.948.770.861.655.699.80
Current Ratio1.511.955.057.948.770.861.655.699.80

Cash flow, annual

Currency USD, millions
MetricTTM2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY
Net Income-16.76-20.85-15.02-15.42-14.32-7.71-3.58-47.60-43.54
Depreciation-0.000.000.000.000.000.000.850.86
Other Funds (Non Cash)2.042.512.312.532.821.510.1417.194.25
Funds from Operations-14.72-18.34-12.72-12.89-11.50-6.20-3.44-29.27-38.43
Extraordinary Item0.000.000.000.000.000.000.000.000.00
Changes in Working Capital-1.063.510.39-0.52-1.58-5.090.120.23-0.64
Cash from Operating Activities-15.79-14.82-12.32-13.41-13.08-11.29-3.32-29.05-39.08
Capital Expenditures0.000.000.000.000.00-0.000.00-0.92-9.60
Net Assets From Acquisitions0.000.000.000.000.000.000.000.00-
Sale of Fixed Assets and Businesses0.000.000.000.000.170.450.000.000.00
Purchase or Sale of Investments-4.100.000.0017.14-16.600.000.000.580.30
Purchase of Investments-4.100.000.00-6.86-29.600.000.00-0.00
Sale Or Maturity of Investments0.000.000.0024.0013.000.000.000.580.30
Other Uses0.000.000.000.000.000.000.00-2.870.00
Other Sources0.000.000.000.000.000.000.000.000.00
Cash from Investing Activities-4.100.000.0017.14-16.430.450.00-3.21-9.30
Cash Dividends Paid0.000.000.000.000.000.000.000.000.00
Change in Capital Stock21.1011.834.750.000.0030.360.002.3735.06
Repurchase of Common Pref Stock0.000.000.000.000.000.000.000.000.00
Sale of Common Pref Stock21.1011.834.750.000.0030.360.002.3735.06
Proceedsfrom Stock Options6.085.43-0.760.000.0029.970.002.0935.03
Issuance or Reduction of Debt, Net0.325.710.000.000.000.000.000.000.00
Change in Long Term Debt0.000.000.000.000.000.000.000.000.00
Issuance of Long Term Debt0.000.000.000.000.000.000.000.000.00
Reduction of Long Term Debt0.000.000.000.000.000.000.000.000.00
Net Financing Active Other Cash Flow0.000.000.000.000.0017.971.160.000.00
Other Financing Activities Uses0.000.000.000.000.00-3.370.000.000.00
Cash from Financing Activities21.4217.544.750.000.0048.341.162.3735.06
Exchange Rate Effect------0.16-0.07-0.83
Net Change in Cash1.532.72-7.583.74-29.5137.49-2.16-29.95-14.15
Free Cash Flow-15.79-14.82-12.32-13.41-13.08-11.29-11.53-29.97-43.74
Preferred Dividends (Cash Flow)--0.000.000.000.000.000.000.00
Deferred Taxes & Investment Tax Credit-0.000.000.000.000.000.000.280.00

Balance sheet, quarterly

Currency USD, millions
Metric2026Q22026Q12025Q42025Q32025Q22025Q1
Cash & Short Term Investments11.551.508.515.836.163.89
Short Term Receivables0.000.000.000.000.000.00
Inventories0.000.000.000.000.000.00
Other Current Assets0.430.680.800.610.261.07
Total Current Assets11.992.189.316.446.414.96
Net Property, Plant & Equipment0.000.000.000.010.030.06
Total Investments and Advances0.000.000.000.000.000.00
Intangible Assets0.000.000.00---
Deferred Tax Assets--0.00---
Other Assets0.000.000.000.390.390.39
Total Assets11.992.189.316.846.845.41
Short Term Debt Incl. Current Port. of LT Debt0.000.000.000.016.540.06
Accounts Payable0.510.560.540.710.621.31
Other Current Liabilities0.110.385.611.521.361.24
Total Current Liabilities0.620.936.162.238.512.61
Long Term Debt0.000.000.000.000.000.00
Provision for Risks Charges0.000.000.000.000.000.00
Deferred Tax Liabilities--0.00---
Other Liabilities0.000.000.000.000.000.00
Total Liabilities0.620.936.162.238.512.61
Non-Equity Reserves0.000.000.000.000.000.00
Preferred Stock - Carrying Value0.000.000.010.000.000.00
Common Equity11.371.253.144.61-1.672.80
Total Shareholders Equity11.371.253.154.61-1.672.80
Accumulated Minority Interest0.000.000.000.000.000.00
Total Equity11.371.253.154.61-1.672.80
Total Liabilities & Stockholders Equity11.992.189.316.846.845.41
Book Value Per Share0.090.011.452.81-2.774.89
Tangible Book Value Per Share0.090.011.452.81-2.774.89
Full-Time Employees--5---
Price to Book Ratio33.981.261.04-1.0460.313.15
Return on Assets-163.84-496.74-250.45-223.71-226.74-192.51
Return on Equity-318.04-931.79-587.59-317.98-755.04-259.00
Return on Invested Capital-15.78-203.63-257.41-64.60--161.89
Quick Ratio19.482.341.512.880.751.90
Current Ratio19.482.341.512.880.751.90

Cash flow, quarterly

Currency USD, millions
Metric2026Q22026Q12025Q42025Q32025Q22025Q1
Net Income-1.91-2.54-8.79-3.52-5.27-4.53
Depreciation--0.000.000.000.00
Other Funds (Non Cash)-0.050.640.860.590.970.24
Funds from Operations-1.96-1.90-7.94-2.93-4.30-4.29
Extraordinary Item0.000.000.000.000.000.00
Changes in Working Capital-0.20-5.114.38-0.130.24-0.76
Cash from Operating Activities-2.16-7.01-3.56-3.06-4.06-5.05
Capital Expenditures0.000.000.000.000.000.00
Net Assets From Acquisitions0.000.000.000.000.000.00
Sale of Fixed Assets and Businesses0.000.000.000.000.000.00
Purchase or Sale of Investments-4.100.000.000.000.000.00
Purchase of Investments-4.100.000.000.000.000.00
Sale Or Maturity of Investments0.000.000.000.000.000.00
Other Uses0.000.000.000.000.000.00
Other Sources0.000.000.000.000.000.00
Cash from Investing Activities-4.100.000.000.000.000.00
Cash Dividends Paid0.000.000.000.000.000.00
Preferred Dividends (Cash Flow)0.000.00-0.000.000.00
Change in Capital Stock12.290.006.322.490.593.15
Repurchase of Common Pref Stock0.000.000.000.000.000.00
Sale of Common Pref Stock12.290.006.322.490.593.15
Proceedsfrom Stock Options-0.020.006.22-0.12-0.01-0.33
Issuance or Reduction of Debt, Net0.000.000.090.245.740.00
Change in Long Term Debt0.000.000.000.000.000.00
Issuance of Long Term Debt0.000.000.000.000.000.00
Reduction of Long Term Debt0.000.000.000.000.000.00
Net Financing Active Other Cash Flow0.000.000.000.000.000.00
Other Financing Activities Uses0.000.000.000.000.000.00
Cash from Financing Activities12.290.006.402.736.323.15
Net Change in Cash6.03-7.012.85-0.332.27-1.90
Free Cash Flow-2.16-7.01-3.56-3.06-4.06-5.05

Revenue breakdown

Revenue split-

Short interest

shares short against float, oldest to newest
SettlementOf floatShares shortFloatAvg volume
2026-10-3015.78%1.1M7.2M896.70K
2026-10-1511.87%0.9M7.2M862.62K
2026-09-3015.06%0.8M5.5M802.33K
2026-09-1516.78%0.9M5.5M713.81K
2026-08-314.48%0.2M4.7M1.23M
2026-08-142.61%0.1M4.7M1.02M
2026-07-312.32%0.1M4.0M1.01M
2026-07-156.46%0.3M4.0M1.01M
2026-06-300.69%0.1M19.9M1.00M
2026-06-1514.26%0.5M3.5M951.39K
2026-05-290.50%0.0M3.5M71.63K
2026-05-151.74%0.1M3.5M54.69K
2026-04-30234.68%0.1M0.0M49.45K
2026-04-153.75%0.1M1.4M54.59K
2026-03-310.93%0.0M1.4M60.83K
2026-03-130.60%0.0M1.4M708.68K
2026-02-271.36%0.0M1.4M692.71K
2026-02-131.25%0.0M1.4M696.47K
2026-01-301.36%0.0M1.4M696.49K
2026-01-154.93%0.1M1.4M686.44K

Option chain

expiry 2026-11-11
TypeStrikeBidAskLastIVOpen intVolumeDeltaThetaVega
No option chain for this symbol.

Latest SEC filings

30
FiledFormDescriptionPeriodLink
2026-10-22SCHEDULE 13D/ASEC
2026-10-22SCHEDULE 13D/ASEC
2026-10-22SCHEDULE 13D/ASEC
2026-10-21SCHEDULE 13D/ASEC
2026-10-208-KCurrent report2026-10-16SEC
2026-10-05S-8Initial registration statement for securities to be offered to employees pursuant to employee benefit plansSEC
2026-09-308-KCurrent report2026-09-29SEC
2026-09-108-KCurrent report2026-09-08SEC
2026-09-088-K/A2026-08-28SEC
2026-09-048-KCurrent report2026-09-02SEC
2026-09-04424B5SEC
2026-09-018-KCurrent report2026-08-28SEC
2026-08-31424B5SEC
2026-08-26424B3SEC
2026-08-25EFFECTEffectiveness filing by commission orderSEC
2026-08-17S-3Registration statement for specified transactions by certain issuers including face-amount certificate companiesSEC
2026-08-1310-QQuarterly report pursuant to Section 13 or 15(d)2026-06-30SEC
2026-08-138-KCurrent report2026-08-10SEC
2026-07-17EFFECTEffectiveness filing by commission orderSEC
2026-07-16DEF 14AProxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 19342026-07-16SEC
2026-06-26SCHEDULE 13D/ASEC
2026-06-26SCHEDULE 13D/ASEC
2026-06-26SCHEDULE 13D/ASEC
2026-06-26SCHEDULE 13D/ASEC
2026-06-26S-3Registration statement for specified transactions by certain issuers including face-amount certificate companiesSEC
2026-06-248-KCurrent report2026-06-17SEC
2026-06-22PRE 14AProxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 19342026-06-22SEC
2026-06-058-KCurrent report2026-06-01SEC
2026-05-1510-QQuarterly report pursuant to Section 13 or 15(d)2026-03-31SEC
2026-05-158-KCurrent report2026-05-15SEC

Insider activity by month

MonthBoughtBuysSoldSells
2026-110000
2026-100000
2026-090000
2026-080000
2026-070000
2026-060000
2026-050000
2026-040000
2026-030000
2026-020000
2026-010000
2025-120000
2025-110000

Institutional holders

Manager% owned
HRT FINANCIAL LP0.18%
GEODE CAPITAL MANAGEMENT, LLC0.13%
UBS Group AG0.05%
JANE STREET GROUP, LLC0.05%
VANGUARD CAPITAL MANAGEMENT LLC0.03%
VANGUARD FIDUCIARY TRUST CO0.01%
MILLENNIUM MANAGEMENT LLC0.01%
BARCLAYS PLC0.01%
MORGAN STANLEY0.01%
SBI Securities Co., Ltd.0.00%

Funds

Fund% owned
Fidelity Nasdaq Composite Index Fund0.05%
Fidelity Extended Market Index Fund0.01%
Morgan Stanley Pathway Small-Mid Cap Equity ETF0.01%
VANGUARD EXTENDED MARKET INDEX FUND0.01%
Fidelity Series Total Market Index Fund0.00%
Fidelity Total Market Index Fund0.00%

OakChart. INDP. Cached 15 minutes.

Some panels did not load: ratings, insider.